|
Volumn 9, Issue 9, 2011, Pages 678-680
|
Novel targets for triple-negative breast cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BEVACIZUMAB;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ESTROGEN RECEPTOR;
GEMCITABINE;
INIPARIB;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;
PROGESTERONE RECEPTOR;
BREAST CANCER;
BREAST FEEDING;
CANCER CHEMOTHERAPY;
CANCER PREVENTION;
CANCER RISK;
CANCER SURVIVAL;
HUMAN;
NOTE;
OBESITY;
OVERALL SURVIVAL;
PROGNOSIS;
PROGRESSION FREE SURVIVAL;
TRIPLE NEGATIVE BREAST CANCER;
TUMOR SUPPRESSOR GENE;
ANTINEOPLASTIC AGENTS;
BRCA1 PROTEIN;
BRCA2 PROTEIN;
BREAST NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
FEMALE;
HUMANS;
NEOPLASMS, BASAL CELL;
POLY(ADP-RIBOSE) POLYMERASES;
PROGNOSIS;
RECEPTOR, ERBB-2;
RECEPTORS, ESTROGEN;
RECEPTORS, PROGESTERONE;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 80054680259
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
Times cited : (3)
|
References (4)
|